

RESSALVA

Atendendo solicitação do autor, o texto completo desta **Tese** será disponibilizado somente a partir de 29/11/2024.



UNIVERSIDADE ESTADUAL PAULISTA
“JÚLIO DE MESQUITA FILHO”

Faculdade de Ciências Farmacêuticas
Campus Araraquara
Programa de Pós-Graduação em Ciências Farmacêuticas



**Development of iron- and zinc-based quantum dots for fluorescence
and magnetic resonance bioimaging applications**

**Desenvolvimento de pontos quânticos à base de ferro e zinco para
aplicações de bioimagem por fluorescência e ressonância magnética**

Thúlio Wliandon Lemos Barbosa

Orientadora (UNESP): Prof. Dra. Leila Aparecida Chiavacci Favorin

Supervisor (Université d'Angers): Dr. Laurent Lemaire

Araraquara - SP

2024



UNIVERSIDADE ESTADUAL PAULISTA
“JÚLIO DE MESQUITA FILHO”

Faculdade de Ciências Farmacêuticas
Campus Araraquara
Programa de Pós-Graduação em Ciências Farmacêuticas



**Development of iron- and zinc-based quantum dots for fluorescence
and magnetic resonance bioimaging applications**

**Desenvolvimento de pontos quânticos à base de ferro e zinco para
aplicações de bioimagem por fluorescência e ressonância magnética**

Thúlio Wliandon Lemos Barbosa

Tese apresentada ao Programa de Pós-graduação
em Ciências Farmacêuticas (Unesp) para obtenção
do título de Doutor em Ciências, área: Pesquisa e
desenvolvimento de Fármacos e medicamentos.

Orientadora (UNESP): Prof Dra. Leila Aparecida
Chiavacci Favorin

Supervisor (Université d'Angers): Dr. Laurent
Lemaire

Araraquara - SP

2024

B238d

Barbosa, Thúlio Wliandon Lemos.

Development of iron- and zinc-based quantum dots for fluorescence and magnetic resonance bioimaging applications = Desenvolvimento de pontos quânticos à base de ferro e zinco para aplicações de bioimagem por fluorescência e ressonância magnética / Thúlio Wliandon Lemos Barbosa. – Araraquara, 2024. 194 f. : il.

Orientadora: Leila Aparecida Chiavacci Favorin.
Coorientador: Laurent Lemaire.

Tese (Doutorado) – Universidade Estadual Paulista. "Júlio de Mesquita Filho". Faculdade de Ciências Farmacêuticas. Programa de Pós-Graduação em Ciências Farmacêuticas. Área de Pesquisa e Desenvolvimento de Fármacos e Medicamentos.

1. Zinco. 2. Ferro. 3. Luminescência. 4. Ressonância magnética. 5. Imagem biológica. I. Favorin, Leila Aparecida Chiavacci, orient. II. Lemaire, Laurent, coorient. III. Título.

Diretoria do Serviço Técnico de Biblioteca e Documentação - Faculdade de Ciências Farmacêuticas
UNESP - Campus de Araraquara

CAPES: 33004030078P6
Esta ficha não pode ser modificada

CERTIFICADO DE APROVAÇÃO

TÍTULO DA TESE: Desenvolvimento de pontos quânticos à base de ferro e zinco para aplicações de bioimagem por fluorescência e ressonância magnética

AUTOR: THÚLIO WLIANDON LEMOS BARBOSA

ORIENTADORA: LEILA APARECIDA CHIAVACCI FAVORIN

Aprovado como parte das exigências para obtenção do Título de Doutor em Ciências, área: Pesquisa e Desenvolvimento de Fármacos e Medicamentos pela Comissão Examinadora:

Profa. Dra. LEILA APARECIDA CHIAVACCI FAVORIN (Participação Presencial)
Departamento de Farmacos e Medicamentos / Faculdade de Ciências Farmaceuticas do Campus de Araraquara da Unesp

Prof. Dr. ARNÓBIO ANTONIO DA SILVA JUNIOR (Participação Virtual)
Departamento de Farmácia / Universidade Federal do Rio Grande do Norte (UFRN)

Profa.Dra. SANDRA HELENA PULCINELLI (Participação Presencial)
Departamento de Química Analítica, Físico-Química e Inorgânica / Instituto de Química do Campus de Araraquara da Unesp

Prof. Dr. FERNANDO LUCAS PRIMO (Participação Presencial)
Departamento de Engenharia de Bioprocessos e Biotecnologia / Faculdade de Ciências Farmaceuticas do Campus de Araraquara da Unesp

Prof. Dr. LUCAS AMARAL MACHADO (Participação Presencial)
Departamento de Fármacos e Medicamentos / Faculdade de Ciências Farmacêuticas do Campus de Araraquara da Unesp

Araraquara, 29 de maio de 2024

Dedico este trabalho à minha mãe, Cleide, um exemplo de força e resiliência, que sempre me apoiou nos momentos mais difíceis e a quem amo muito.

Acknowledgements

I would like to thank everyone who has contributed in any way to the completion of this thesis. As you know, it has been a very difficult time, not only for me, but for everyone, as we have lived through a pandemic that has greatly affected my efforts to complete this thesis. However, I followed my dream of getting a Ph.D. from a prestigious university, and I had the cooperation of many people who helped me complete this journey with good results. As well as the opportunity to study abroad and improve my professional performance.

I would like to thank my family, my parents Cleide and Wliandon and my siblings Natália, Najara and Thiago, for their support and understanding that at this stage of my life I had to make many choices and miss important moments that would be fundamental for my professional life.

I would like to thank those who have become my family in Araraquara and who have given me the strength to carry on and never give up. To my friends Marina, Natália, Rafael, Péricles, Mariana and Bruna for their partnership. To the students I had the honor of helping Mariah, Bruno and Larissa.

A special thanks to two important friends I made during my doctorate, Guilherme Esquibola and Ewerton Mima, who have always supported me and whose friendship I would like to carry with me for the rest of my life.

To the friends I made in Angers, Shayan, Melina, Oksana, Cecile, Sebastian and Jaspe, who received me and helped me in some way to complete my thesis.

I would like to thank my professional colleagues, especially my supervisors, Leila Aparecida Chiavacci and Laurent Lemaire, who gave me a broad view of what it means to be a trained professional in the field I love to work. A thank to Isabelle for her support in the biological analyses, to Olivier for his teaching on nanomaterials and the use of the Liophilizer, and to Patrick for welcoming me to the INSERM laboratory.

I am grateful to the UNESP-Araraquara and University of Angers for their hospitality and support during my sandwich Ph.D. period. The experience and resources provided by both institutions were fundamental to the development of this work.

I also thank the CAPES PrInt Program (CAPES/PRINT - Edital nº 41/2017) for the financial support through the scholarship grant, which made my stay and research abroad possible. Without this support, the realization of this thesis would not have been possible.

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

RESUMO

Devido à toxicidade associada a compostos inorgânicos como cádmio e gadolínio, a seleção de agentes de contraste para diagnóstico é crucial. Compostos à base de zinco e ferro surgiram como alternativas potenciais devido à sua abundância, baixo custo e baixa toxicidade. O óxido de zinco (ZnO) oferece alta luminescência devido ao seu alto rendimento quântico, enquanto o óxido de ferro (IO) exibe propriedades de relaxividade adequadas para ressonância magnética. Este projeto visa sintetizar e explorar as propriedades luminescentes e magnéticas de agentes de contraste à base de ferro e zinco para aplicações potenciais de imagem diagnóstica. Compostos incluindo ZnO, IO, cobre-índio-zinco-enxofre/sulfeto de zinco (CIS/ZnS) e óxido de zinco dopado com ferro (FeZnO) foram obtidos e incorporados em um copolímero de ácido polilático-glicólico (PLGA) visando aumentar a sua estabilidade em meios biológicos. A caracterização dos sistemas poliméricos foi realizada usando espalhamento dinâmico de luz (DLS) e microscopia eletrônica de transmissão (TEM). As propriedades ópticas foram examinadas por meio de espectros de absorção e fluorescência, enquanto as propriedades magnéticas foram quantificadas por meio de medidas de tempo de relaxação transversal e longitudinal. O primeiro sistema foi avaliado baseado em nanopartículas de PLGA, contendo ZnO e IO. Em uma proporção de PLGA:ZnO:IO de 10:6:1 foi possível obter um agente de contraste duplo com emissão em 540 nm ao ser excitado em 343 nm e um forte efeito T2 com uma relaxividade r_2 de 171 mmol L⁻¹ s⁻¹ a 7 teslas. O tamanho das nanopartículas determinado por DLS foi de aproximadamente 200 nm com um PDI abaixo de 0,3, enquanto as partículas de ZnO e IO incorporadas tinham cerca de 4 nm e 8 nm, respectivamente. A investigação de um segundo agente de contraste envolvendo a dopagem das nanopartículas de ZnO com ferro revelou que uma concentração molar de Fe entre 0,1 e 1,0% e um tempo de adição de dopante de 30 minutos produziram material luminescente com emissão em 540 nm quando excitado a 343 nm, com tamanhos de nanopartículas de aproximadamente 4 nm. As propriedades magnéticas exibiram propriedades de relaxação T1 e T2, com uma relaxividade de $r_2 = 18,47$ mmol L⁻¹ s⁻¹ e $r_1 = 1,79$ mmol L⁻¹ s⁻¹ a 7T para a amostra FeZnO0.1. A investigação de um terceiro agente de contraste baseado em compostos de cobre-índio-zinco-enxofre revelou que as nanopartículas dopadas com Fe e sistemas núcleo-casca perderam suas propriedades de luminescência. No entanto, a coencapsulação de agentes

de contraste à base de cobre-índio-zinco-enxofre e óxido de ferro dentro do polímero PLGA resultou na produção de um sistema caracterizado por uma forte emissão a 650 nm ao ser excitado a 365 nm e 525 nm, bem como propriedades magnéticas exibindo um efeito T2 a 7T. No geral, este estudo destaca o potencial de agentes de contraste à base de ferro e zinco para aplicações de imagem diagnóstica.

Palavras-chave: zinco; ferro; luminescência; ressonância magnética; imagem biológica.

ABSTRACT

Due to the toxicity associated with inorganic compounds like cadmium and gadolinium, selecting contrast agents for diagnostics is crucial. Zinc- and iron-based compounds have emerged as potential alternatives due to their abundance, low cost, and low toxicity. Zinc oxide (ZnO) offers high luminescence due to its high quantum yield, while iron oxide (IO) exhibits relaxivity properties suitable for magnetic resonance imaging (MRI). This thesis aims to synthesize and explore the luminescent and magnetic properties of iron- and zinc-based contrast agents for potential diagnostic imaging applications. Compounds including ZnO, IO, copper-indium-zinc-sulfide/zinc sulfide (CIS/ZnS), and iron-doped zinc oxide (FeZnO) were obtained and incorporated into a poly(lactic-co-glycolic acid) (PLGA) copolymer to increase their stability in biological environments. The characterization of the polymer systems was carried out using dynamic light scattering (DLS) and transmission electron microscopy (TEM). Optical properties were examined through absorption and fluorescence spectra, while magnetic properties were quantified using transverse and longitudinal relaxation time measurements. The first system was evaluated based on PLGA nanoparticles containing ZnO and IO. With a PLGA:ZnO:IO ratio of 10:6:1, a dual contrast agent was obtained with emission at 540 nm when excited at 343 nm and a strong T2 effect with an r_2 relaxivity of $171 \text{ mmol L}^{-1} \text{ s}^{-1}$ at 7 teslas. The size of the nanoparticles determined by DLS was approximately 200 nm with a PDI below 0.3, while the incorporated ZnO and IO particles were around 4 nm and 8 nm, respectively. Investigation of a second contrast agent involving doping ZnO nanoparticles with iron revealed that an iron molar concentration between 0.1% and 1.0%, and a dopant addition time of 30 minutes, produced luminescent material with emission at 540 nm when excited at 343 nm, with nanoparticle sizes of approximately 4 nm. The magnetic properties displayed both T1 and T2 relaxation characteristics, with $r_2 = 18.47 \text{ mmol L}^{-1} \text{ s}^{-1}$ and $r_1 = 1.79 \text{ mmol L}^{-1} \text{ s}^{-1}$ at 7T for the FeZnO0.1 sample. The investigation of a third contrast agent based on copper-indium-zinc-sulfide compounds revealed that Fe-doped nanoparticles and core-shell systems lost their luminescence properties. However, co-encapsulation of copper-indium-zinc-sulfide-based contrast agents and iron oxide within the PLGA polymer resulted in a system characterized by strong emission at 650 nm when excited at 365 nm and 525 nm, along with magnetic properties exhibiting a T2 effect at 7T. Overall, this

study highlights the potential of iron- and zinc-based contrast agents for diagnostic imaging applications.

Keywords: zinc; iron; luminescence; magnetic resonance imaging; biological imaging.

List of Figures

Figure I.1. Jablonski Diagram.....	36
Figure I.2. Energy level diagram.	37
Figure I.3. Variation of the gap energy as a function of particle size.	37
Figure I.4. Molecular structure of GPTMS.	49
Figure I.5. Molecular structure of Oleic acid.	49
Figure I.6. Molecular structure of PLGA.	50
Figure II.1. Flowchart of ZnO QDs (a) and FeZnO QDs (b) production, along with their surface modification (c) using GPTMS and oleic acid. *Iron source: iron chloride, iron acetate, or iron nitrate.	64
Figure II.2. Flowchart of Fe ₃ O ₄ NPs production with their surface modification using oleic acid.	65
Figure II.3. Flowchart of CIS/ZnS NPs (a) and FeZIS/ZnS NPs (b) production with their surface modification using oleic acid and oleylamine.	67
Figure II.4. Flowchart of PLGA NPs production containing QDs incorporated.	69
Figure III.1 Pictures of a) System of zinc acetate precursor preparation; b) colloidal suspension of ZnO at day light; c) colloidal suspension of ZnO in a UV chamber when excited in a 365 nm lamp.	75
Figure III.2. Picture of ZnO ethanolic suspensions coated with different concentrations of oleic acid and observed by UV chamber at 365 nm: a) 50 μL OA (14 mmol L^{-1}), b) 60 μL OA (17 mmol L^{-1}), c) 75 μL OA (21 mmol L^{-1}), d) 100 μL OA (28 mmol L^{-1}), and e) 125 μL OA (35 mmol L^{-1}). Luminescence was observed by UV chamber when excited in a 365 nm lamp.	76
Figure III.3. Pictures of ZnO NPs coated by a) 60 μL (17 mmol L^{-1}), b) 75 μL (21 mmol L^{-1}), c) 100 μL (28 mmol L^{-1}) and d) 125 μL (35 mmol L^{-1}) of oleic acid and dispersed in ethanol.	77
Figure III.4. Infrared spectra of uncoated ZnO NP compared to ZnO samples coated with 60 μL (17 mmol L^{-1}), 75 μL (21 mmol L^{-1}), 100 μL (28 mmol L^{-1}) and 125 μL (28 mmol L^{-1}) of oleic acid.	77

Figure III.5. Pictures of ZnO samples coated with 60 μL (17 mmol L^{-1}), 75 μL (21 mmol L^{-1}), 100 μL (28 mmol L^{-1}) and 125 μL (28 mmol L^{-1}) of oleic acid dispersed in DCM.	78
Figure III.6. Emission spectra of ZnO NPs coated with different concentrations of 75 μL (21 mmol L^{-1}), 100 μL (28 mmol L^{-1}) and 125 μL (35 mmol L^{-1}) of oleic acid dispersed in DCM with a final concentration of 40 mg mL^{-1} . Excitation wavelength in 343 nm.	79
Figure III.7. Pictures of a) IO/OA coated in ethanol separated by magnet; and b) IO/OA coated dispersed in DCM at the concentration of 40 mg mL^{-1}	80
Figure III.8. Pictures of IO/OA coated dispersed in DCM after 24 hours of synthesis and storage at RT and with Mf applied (right image).	81
Figure III.9. Representation of PLGA:IO particles solutions, arranged from left to right: PLGA:IO 10:1, 10:2, 10:3, and 10:4 (a). Excitation spectra with emission at 540 nm (b), emission spectra with excitation at 343 nm (c), and emission spectra with excitation at 350 nm (d).	83
Figure III.10. Pictures of samples after synthesis and excited by the 245 nm lamp of PLGA:ZnO proportion of a) 10:2, b) 10:4, c) 10:6, and d) 10:8.	84
Figure III.11. Spectroscopic analysis of PLGA:ZnO (w:w, mg) in proportion 10:2, 10:4, 10:6, and 10:8. a) Absorbance spectra between 200 to 400 nm; b) Excitation spectra, emission in 540 nm; c) Emission spectra, excitation in 343 nm; and d) Emission spectra, excitation in 350 nm.	85
Figure III.12. Pictures of PLGA:ZnO samples after washing and excitation with a 365 nm lamp: a) 10:2; b) 10:4; c) 10:6; and d) 10:8.	86
Figure III.13. Different ratios of ZnO and IO dispersed in DCM. a) Emission spectrum, excitation at 343 nm; b) Emission spectrum, normalized intensity; c) plot of intensity maximum of ZnO:IO in DCM at different ratios; and d) wavelength maximum of ZnO:IO in DCM at different ratios.	88
Figure III.14. Spectra of samples of PLGA:ZnO:IO, ZnO = 8 mg, IO = 1, 2, 3, and 4 mg. a) Emission spectra with excitation wavelength at 350 nm, b) emission spectra with excitation wavelength at 343 nm, and c) excitation spectra with emission wavelength at 540 nm.	90

Figure III.15. Luminescence results of PLGA:ZnO:IO, with differences proportion of ZnO: a) excitation spectra with emission in 540 nm, b) emission spectra with excitation in 343 nm, and c) emission spectra with excitation lamp in 350 nm.	92
Figure III.16. PLGA:ZnO:IO suspensions in the ratios a) 10:6:1, and b) 10:8:1 with Mf application.	93
Figure III.17. Infrared spectra of PLGA:ZnO:IO 10:6:1 NP. a) infrared analysis between 400-4000 cm^{-1} , b) magnified between 400-600 cm^{-1}	94
Figure III.18. TEM results of PLGA:ZnO:IO NPs at 10:0:0 (a,b,c), 10:6:0 (d,e,f), 10:8:0 (g,h,i), 10:0:1 (j,k,l), 10:6:1 (m,n,o), and 10:8:1 (p,q,r) at different scale bars (50, 100, and 200 nm).	95
Figure III.19. Histogram spectra of PLGA:ZnO:IO NPs with different nominal ratio.	96
Figure III.20. TEM of ZnO/OA and IO/OA NPs size. Scale bars: 20 nm (10:0:1, 10:6:0 and 10:8:1), and 50 nm (10:0:0).	97
Figure III.21. Size analysis of NPs encapsulated within PLGA was conducted for PLGA:ZnO:IO samples with nominal ratio of 10:6:1 and 10:8:1, using scale bars of 20 nm and 50 nm.	98
Figure III.22. Size of IO and ZnO from PLGA:ZnO:IO NPs in the nominal ratio of 10:0:1 (a), 10:6:0 (b), 10:6:1 (c), 10:8:0 (d), and 10:8:1 (e).	99
Figure III.23. MRI results of PLGA:ZnO:IO samples: a) PLGA; b) PLGA:ZnO 10:8; c) PLGA:ZnO 10:6; d) PLGA:IO 10:1; e) PLGA:ZnO:IO 10:6:1; and f) PLGA:ZnO:IO 10:8:1. MRI results of T2 weighting left and T1 weighting right. The concentration of the samples is expressed in 2.5 mg mL^{-1}	100
Figure III.24. Relaxivity calculation for PLGA samples containing IO and ZnO. Calculation made from the concentration of iron in each sample. Graph of samples a) PLGA:IO 10:1, b) PLGA:ZnO:IO 10:6:1 and PLGA:ZnO:IO 10:8:1.	102
Figure IV.1. Pictures of (top) Iron chloride solution before (a) and after (b) heating for 2 hours. (bottom) Iron acetate solution, a) before heating, b) after heating, c) after heating with addition of acidic solution, d) after heating with addition of basic solution.	108

Figure IV.2. Results of FeZnO with iron nitrate precursor ($\% = [\text{Fe}]/[\text{Fe}+\text{Zn}] * 100\%$): a) pictures of photoluminescence of ZnO NPs doped with iron in proportions of 1, 5, 10, 15 and 20%; b) Diffractogram of FeZnO samples in proportions of 1, 5, 10, 15 and 20%. c) Absorption spectra of FeZnO samples in proportions of X = 1, 5, 10, 15 and 20%.....	110
Figure IV.3. Pictures of photoluminescence of FeZnO NPs in proportions of 0.1, 0.2, 0.3 and 0.4 % added 0 and 30 minutes after the start of the reaction. Images are shown in UV chamber with excitation in 365 nm and 254 nm.	111
Figure IV.4 Emission spectra (a) of FeZnO with iron concentration between 0.1 and 0.5 %, and a doping time of 30 min, and emission spectra with the normalized intensity (b). Samples excited at the wavelength of 365 nm.	112
Figure IV.5. Pictures of FeZnO with different times of addition of the iron precursor and emission analysed in a UV chamber with excitation at 254 nm. The samples are shown from the left to the right: Fe doped ZnO ($[\text{Fe}]/[\text{Fe}+\text{Zn}]*100\%$ in mol L^{-1}) = 0, 0.1, 0.5, 1, 3, 5, 10, 15 and 20%.....	113
Figure IV.6. Luminescence and absorbance spectra of FeZnO samples synthesized from iron acetate. The samples are divided by doping time: Time 0 with a) spectra of absorbance, b) excitation using emission at 540 nm, c) emission using excitation at 343 nm, and d) emission with normalized intensity; Time 15 with e) spectra of absorbance, f) excitation using emission at 540 nm, g) emission using emission at 343 nm, and h) emission with normalized intensity; and time 30 with i) spectra of absorbance, j) excitation using emission at 540 nm, k) emission using emission at 343 nm, and l) emission with normalized intensity.	114
Figure IV.7. Intensities of the samples according to doping time. Emission intensity at 540 nm when excited at 343 nm.	116
Figure IV.8. Luminescence study of FeZnO samples disperse in EtOH prepared with iron acetate (a, d, g, j), iron chloride (b, e, h and k) and iron nitrate (c, f, i, l) for absorbance spectra (a, b, c), excitation spectra (absorption spectra) (d, e, f), emission spectra (g, h, i) and normalized intensity emission (j, k l).	117
Figure IV.9. Graphic intensity of Fe doped ZnO at Fe concentration between 0 and 1% ($\% = [\text{Fe}]/[\text{Fe}+\text{Zn}]*100$, mol L^{-1}) prepared with different iron sources (iron nitrate, iron chloride and iron acetate). Maximum luminescence intensity in 540 nm.	118

Figure IV.10. MRI analysis of GPTMS coated FeZnO samples using iron acetate with 0.1% (a), 1.0% (b), 5.0% (c) and 20% (d) of iron. The T2-weighted (left) and T1-weighted (right) Mr images are shown.	119
Figure IV.11. MRI analysis of GPTMS coated FeZnO samples using iron chloride with 0.1% (a), 1.0% (b), 5.0% (c) and 20% (d) iron. The T2-weighted (left) and T1-weighted (right) Mr images are shown.	120
Figure IV.12. Position of the samples in the MRI analyses.	122
Figure IV.13. T2-weighted and T1-weighted images of particles coated with FeZnO with varying iron proportions. The samples were synthesized using iron acetate as the iron precursor, and the doping time was tested (0, 15, and 30 minutes).	122
Figure IV.14. Graphs of relaxation effects induced by GPMTS-coated FeZnO samples with different proportions of [Fe]/[Fe+Zn], mol/mol %, with different doping time. T2 effect (a) and T1 effect (b).	123
Figure IV.15. Sample distribution in the MRI analyses.	124
Figure IV.16. T2-weighted and T1-weighted outcomes of FeZnO samples containing 0.5% iron. The concentration ranges from 0.625 to 20 mg mL ⁻¹	124
Figure IV.17. Relaxivity plots of FeZnO _{0.5} samples in different doping time. Relaxivity for r2 (a) and r1 (b).	126
Figure IV.18. T1 and T2 values of FeZnO-GPTMS in the range of 0 to 1.0%.	127
Figure IV.19. Scatter plot showing relaxivity as a function of iron concentration for FeZnO samples. Relaxivity for r2 (a), and r1 (b).	129
Figure IV.20. Diffractogram of Fe-ZnO samples with varying concentrations and consistent doping time for 0 min (a), 15 min (b), and 30 min (c); and with differing doping times and consistent concentration for FeZnO 0.1 (d), FeZnO 0.5 (e), and FeZnO 1.0 (f).	130
Figure IV.21. XAS spectra (XANES + EXAFs) at the iron atom's K-edge energy for different FeZnO samples. (a) Different doping times at the same iron ratio, and (b) Different iron ratios at the same doping time.	132
Figure IV.22. XAS spectra (XANES + EXAFs) at the zinc atom's K-edge energy for different Fe-ZnO samples. (a) Different doping times at the same iron ratio, and (b) Different iron ratios at the same doping time.	133
Figure IV.23. Luminescence of Fe-ZnO/OA compounds dispersed in DCM: a) emission spectra, excitation in 343 nm; b) emission spectra, normalized intensity; and c) maximum intensity of emission.	135

Figure IV.24. Analysis of the luminescence results of the Fe-ZnO samples with iron concentrations of 0, 0.1, 0.5 and 1.0 %.....	138
Figure IV.25. TEM analysis of PLGA:FeZnO0.1. Different scale bars are shown in a) 100 nm, b) 100 nm; c) 50 nm and d) 20 nm.	138
Figure IV.26. TEM analysis of PLGA:FeZnO0.5. Different scale bars are shown in a) 100 nm, b) 100 nm; c) 50 nm and d) 20 nm.	139
Figure IV.27. TEM analysis of PLGA:FeZnO1.0. Different scale bars are shown in a) 100 nm, b) 100 nm; c) 50 nm and d) 20 nm.	140
Figure IV.28. TEM analysis of PLGA:ZnO. Different scale bars are shown at a) 50 nm and b) 20 nm.	141
Figure IV.29. Histogram of NPs size inside of PLGA of a) ZnO, b) FeZnO0.1, c) FeZnO0.5, and FeZnO1.0.	141
Figure IV.30. Mr results of PLGA:FeZnO: a) T2 map (TR = 2000 ms; TE = 8 ms); and b) T1 map of PLGA:FeZnO (TR = 400 ms; TE = 8 ms).	142
Figure V.1. Luminescence spectra of a) excitation (emission at 600 nm); b) emission (excitation at 400 nm); and c) emission (excitation at 500 nm), and picture of d) diluted to 0.4 mg mL ⁻¹ (10 uL in 1000 uL DCM) and excited at 254 nm.	149
Figure V.2. Infrared spectra of CIS/ZnS.	150
Figure V.3. TG and DTA spectra for CIS/ZnS sample.....	151
Figure V.4. Different concentrations of CIS/ZnS with different concentrations of IO and their interference on luminescence. Excitation spectra with emission at 600 nm (a), Emission spectra with excitation at 365 nm (b), and Emission spectra with excitation at 525 nm (c).	153
Figure V.5. Luminescence properties of PLGA:CIS/ZnS samples in mass ratios of 10:1, 10:2, 10:3, and 10:4. a) Absorbance spectra; b) Comparison of maximum emission when excited at 365 nm and 525 nm; c) Emission spectra, for excitation at 365 nm; d) Emission spectra, for excitation at 525 nm.	155
Figure V.6. Luminescence properties of PLGA:CIS/ZnS:IO samples in mass ratios of 10:2:1, 10:3:1, and 10:4:1. a) Absorbance spectra; b) Comparison of maximum emission when excited at 525 nm and 365 nm; c) Emission spectra, excited at 365 nm; d) Emission spectra, excited at 525 nm.	157
Figure V.7. Morphology of PLGA:CIS/ZnS 10:4 by TEM analysis. Different scale bars are used in a) 50 nm, and b) 20 nm.	158

Figure V.8. Morphology analysis of PLGA:CIS/ZnS:IO 10:4:1 by TEM. Scale bar in 50 nm.	159
Figure V.9. MRI analysis on PLGA:CIS/ZnS:IO samples. a) Sample position; b) T2 weighted image (TR = 2000 ms, TE = 104 ms); c) T1 weighted image (TR = 2000 ms; TE = 104 ms).	160
Figure V.10. Infrared spectra of CISZnS, FeCISZnS 30 min, FeCISZnS 60 min, FeCISZnS 90 min samples.	161
Figure V.11. TG and DTA spectra for CIS/ZnS samples in comparison to FeCIS/ZnS samples.	163
Figure V.12. Optical properties of colloidal FeCIS Fluorescence spectra of CISZnS and FeCIS/ZnS QDs excited at 365 nm (a) and 516 nm (b). Absorption spectrum (c) of CIS/ZnS compared to FeCIS/ZnS.	164
Figure V.13. Fluorescence spectra for ZnO@CIS/ZnS samples (a, b, c), FeZnO0.1@CIS/ZnS (d, e, f), FeZnO0.5@CIS/ZnS (g, h, i), and FeZnO1.0@CIS/ZnS (j, k, l). Emission spectra with excitation at 343 nm (a, d, g, j), at 365 nm (b, e, h, k), and absorption spectra with emission at 570 nm (c, f, i, l).	166
Figure V.14. Emission spectrum with excitation at 343 nm of ZnO@CIS/ZnS 80:20 and FeZnO0.1@CIS/ZnS 80:20 samples compared to pristine ZnO.	167
Figure VI.1. Cytotoxicity Test Methodology.....	172
Figure VI.2. Plot of cell viability after 4 h incubation at PLGA particle concentrations between 0.0078 and 128 $\mu\text{g mL}^{-1}$ (n=3, mean $\pm$ SD).	174
Figure VI.3. Plot of cell viability after 24 h incubation at PLGA particle concentrations between 0.0078 and 128 $\mu\text{g mL}^{-1}$ (n=3, mean $\pm$ SD).	174
Figure VI.4. Uptake cells by luminescence assay for PLGA particles containing ZnO and IO NP. Time of incubation of 4 hours (a) and 24 hours (b). Excitation wavelength in 343 nm, and emission wavelength 540 nm. (n=3, mean $\pm$ SD).	175
Figure VI.5. Pictures of morphological analysis of THP-1 cells in plate after uptake assay treated with PLGA particles. a) untreated cells after 4 hours; b) untreated cells after 24 hours; c) cells treated with PLGA 16 $\mu\text{g mL}^{-1}$, uptake after 4 hours; d) cells treated with PLGA 16 $\mu\text{g mL}^{-1}$, uptake after 24 hours; e) cells treated with PLGA 32 $\mu\text{g mL}^{-1}$, uptake after 4 hours; f) cells treated with PLGA 32 $\mu\text{g mL}^{-1}$, uptake after 24 hours; g) cells treated with PLGA 64 $\mu\text{g mL}^{-1}$, uptake after 4 hours; h) cells treated with PLGA 64 $\mu\text{g mL}^{-1}$, uptake after 24 hours.	177

Figure VI.6. Morphological analysis of THP-1 cells in plate after uptake assay treated with PLGA:IO particles. a) untreated cells after 4 hours; b) untreated cells after 24 hours; c) cells treated with PLGA:IO 16 $\mu\text{g mL}^{-1}$, uptake after 4 hours; d) cells treated with PLGA:IO 16 $\mu\text{g mL}^{-1}$, uptake after 24 hours; e) cells treated with PLGA:IO 32 $\mu\text{g mL}^{-1}$, uptake after 4 hours; f) cells treated with PLGA:IO 32 $\mu\text{g mL}^{-1}$, uptake after 24 hours; g) cells treated with PLGA:IO 64 $\mu\text{g mL}^{-1}$, uptake after 4 hours; h) cells treated with PLGA:IO 64 $\mu\text{g mL}^{-1}$, uptake after 24 hours.178

Figure VI.7. Morphological analysis of THP-1 cells in plate after uptake assay treated with PLGA:ZnO particles. a) untreated cells after 4 hours; b) untreated cells after 24 hours; c) cells treated with PLGA:ZnO 16 $\mu\text{g mL}^{-1}$, uptake after 4 hours; d) cells treated with PLGA:ZnO 16 $\mu\text{g mL}^{-1}$, uptake after 24 hours; e) cells treated with PLGA: ZnO 32 $\mu\text{g mL}^{-1}$, uptake after 4 hours; f) cells treated with PLGA:ZnO 32 $\mu\text{g mL}^{-1}$, uptake after 24 hours; g) cells treated with PLGA:ZnO 64 $\mu\text{g mL}^{-1}$, uptake after 4 hours; h) cells treated with PLGA:ZnO 64 $\mu\text{g mL}^{-1}$, uptake after 24 hours.179

Figure VI.8. Morphological analysis of THP-1 cells in plate after uptake assay treated with PLGA:ZnO:IO particles. a) untreated cells after 4 hours; b) untreated cells after 24 hours; c) cells treated with PLGA:ZnO:IO 16 $\mu\text{g mL}^{-1}$, uptake after 4 hours; d) cells treated with PLGA:ZnO:IO 16 $\mu\text{g mL}^{-1}$, uptake after 24 hours; e) cells treated with PLGA:ZnO:IO 32 $\mu\text{g mL}^{-1}$, uptake after 4 hours; f) cells treated with PLGA:ZnO:IO 32 $\mu\text{g mL}^{-1}$, uptake after 24 hours; g) cells treated with PLGA:ZnO:IO 64 $\mu\text{g mL}^{-1}$, uptake after 4 hours; h) cells treated with PLGA:ZnO:IO 64 $\mu\text{g mL}^{-1}$, uptake after 24 hours.180

Figure VI.9. Intensity and behaviour of Fe-ZnO samples when dispersed in cellular medium and luminescence stability study over a 24-hour period (n=3).181

Figure VI.10. Cellular uptake assay with FeZnO samples after 6 and 24 hours of incubation (n=3). Samples excited at 343 nm and emitting at 540 nm.182

List of Tables

Table II.1. Amount of the Zn precursor and Fe precursor.....	62
Table II.2. Nominal mass proportion of FeZnO@CIS/ZnS samples.....	68
Table III.1. Nominal ratio of the IO to PLGA used in the experiments.....	82
Table III.2. Size of PLGA:IO particles in DLS analyses.....	82
Table III.3. Nominal ratio of the ZnO to PLGA used in the experiments.....	84
Table III.4. DLS analysis of PLGA:ZnO NPs for size determination.....	85
Table III.5. Size of PLGA NPs containing ZnO in different proportions after 5 days of dispersion in water.	87
Table III.6. IO ratio as a function of the PLGA particle size, with a constant amount of ZnO.	89
Table III.7. Size of PLGA NPs containing ZnO in different proportions after 15 days of dispersion in water and storage at approximately 4°C.	89
Table III.8. PLGA:ZnO:IO samples with different amounts of ZnO and IO	91
Table III.9. PLGA:ZnO:IO samples with different amounts of ZnO.....	91
Table III.10. PLGA:ZnO:IO samples analysed by MRI.	93
Table III.11. DLS and TEM analysis of the size of PLGA:ZnO:IO.	96
Table III.12. Size of ZnO and IO analysed by TEM and calculated by Gaussian curve.	98
Table III.13. T1 and T2 values of PLGA:ZnO:IO samples.	100
Table III.14. Amount of iron measured in PLGA:ZnO:IO samples by ICP technique.....	101
Table III.15. Report of 1/T2 in relation to the concentration of iron.	101
Table III.16. Relaxivity (r2) of PLGA:ZnO:IO samples.	102
Table III.17. Zeta potential of PLGA:ZnO:IO samples.	103
Table IV.1. FeZnO synthesis with different doping times.....	113
Table IV.2. Maximum emission intensity at 540 nm, excitation at 343 nm, with different dopant addition times.	115
Table IV.3. T2 and T1 values for solution prepared with different amounts of FeZnO synthesised from iron acetate.	119
Table IV.4. T2 and T1 values for solution prepared with different amounts of FeZnO synthesised from iron chloride.	121

Table IV.5. Magnetic Effect Comparison between Iron Chloride and Iron Acetate used as iron source.	121
Table IV.6. T2 values of GPTMS coated FeZnO with different proportion of Fe in mol %, samples concentration in 20 mg mL ⁻¹	123
Table IV.7. T1-weighted values of FeZnO with different proportions of Fe in mol%, sample concentration in 20 mg mL ⁻¹	123
Table IV.8. T2 values for different concentration of FeZnO 0.5% and relaxation time calculation.	125
Table IV.9. T1 values for different concentration of FeZnO 0.5 % and the calculation of relaxation time.	125
Table IV.10. ICP calculation of Fe in FeZnO0.5 samples with different doping time.....	125
Table IV.11. Relaxivity values of FeZnO0.5 samples with different doping time. ...	126
Table IV.12. T1 and T2 values for the FeZnO-GPTMS samples with different concentration of iron (0.1, 0.5 and 1.0 %).	127
Table IV.13. T2 values for Fe-ZnO samples between 0.1, 0.5 and 1.0%.....	128
Table IV.14. T1 values for Fe-ZnO samples between 0.1, 0.5 and 1.0%.....	128
Table IV.15. ICP calculation of Fe in FeZnO samples with different iron concentration: 0.1, 0.5, and 1.0%.....	128
Table IV.16. Relaxivity value of Fe-ZnO at concentration of 0.1%, 0.5%, and 1.0% Fe.	129
Table IV.17. Particle Size of Fe-ZnO samples calculated using the Scherrer equation (mean ± sd).	131
Table IV.18. Oxidation-reduction patterns of Fe-ZnO samples based on XANES spectra for the Fe band.	132
Table IV.19. Mass yield of FeZnO NPs.....	134
Table IV.20. Synthesis conditions of PLGA:FeZnO.....	136
Table IV.21. Results of DLS size analysis of PLGA:Fe-ZnO samples.....	136
Table IV.22. Size and zeta potential of PLGA:Fe-ZnO samples after 7 days of preparation.....	137
Table IV.23. Size of FeZnO NP by Gaussian curve built from Histogram.	142
Table IV.24. T2 map values for PLGA:FeZnO samples.	143
Table IV.25. T1 map values for PLGA:FeZnO samples.	143

Table V.1. Intensities of luminescence peak of samples containing CIS / ZnS and IO dispersed in DCM.	152
Table V.2. PLGA:CIS/ZnS Samples	154
Table V.3. DLS results of PLGA:CIS/ZnS.....	154
Table V.4. Code of PLGA:CIS/ZnS samples.	155
Table V.5. Size and zeta potential of PLGA:CIS/ZnS particles in PVA/T80 suspension (n=3)	156
Table V.6. Stability assay of PLGA:CIS/ZnS analysed after 7 days of synthesis (n=3)	156
Table V.7. Code of PLGA:CIS/ZnS:IO samples.....	157
Table VI.1 Cell viability after 4 hours exposure to PLGA NPs (n=3, mean $\pm$ SD).	173
Table VI.2. Cell viability after 24 hours exposure to PLGA NPs (n=3, mean $\pm$ SD).	173
Table VI.3. Uptake by THP1 cells assessed by luminescence for the PLGA particles. Time of incubation of 4 hours (a) and 24 hours (b). Excitation wavelength in 343 nm, and emission wavelength 540 nm. (n=3, mean $\pm$ SD).	176

List of abbreviations

AE	-	Adverse Effects
CA	-	Contrast Agents
CNS	-	Central Nervous System
CT	-	Computed tomography
DDT	-	1-dodecanotiol
DCM	-	Dicloromethane
GI	-	Gastrointestinal
GPTMS	-	3-glycidoxypopyl)trimethoxysilane
IO	-	Iron Oxide
FeZnO	-	Iron-doped Zinc Oxide
Mf	-	Magnetic Field
Mm	-	Magnetic Moment
Mp	-	Magnetic Properties
Mr	-	Magnetic ressonance
MRI	-	Magnetic ressonance Imaging
NP	-	Nanoparticle
PLGA	-	Poly(lactic-co-glycolic acid)
PLGA:IO	-	PLGA + iron oxide NP
PLGA:ZnO	-	PLGA + zinc oxide NP
PLGA:FeZnO-	-	PLGA + iron-doped Zinc Oxide NP
PLGA:ZnO:IO-	-	PLGA + zinc oxide + iron oxide NP
QD	-	Quantum Dot
RT	-	Repetition time
RE	-	Echo time
SPION	-	Superparamagnetic Iron Oxide Nanoparticle
TEM	-	Transmission electron microscopy
T1	-	Spin-lattice relaxation
T2	-	Spin-spin relaxation

ZnO - Zinc oxide

Summary

INTRODUCTION.....	22
REFERENCES	26
OBJECTIVE.....	31
CHAPTER I. LITERATURE REVIEW.....	33
1.1 CONTRAST AGENTS: BIOAVAILABILITY AND TOXICITY	33
1.2 NANOMATERIALS: LUMINESCENCE AND MAGNETIC PROPERTIES	35
1.2.1 Luminescence Proprieties	35
1.2.2 Magnetic Properties of Superparamagnetic Materials	37
1.3 IMAGING DIAGNOSTICS: FLUORESCENCE AND MAGNETIC RESONANCE IMAGING	38
1.3.1 Fluorescence Imaging System	39
1.3.2 Magnetic Resonance Imaging (MRI).....	40
1.4 NANOPARTICLES OF IRON AND ZINC	41
1.4.1 Zinc oxide quantum dots.....	42
1.4.1.1 Enhancing ZnO Luminescence: The Role of Doping	43
1.4.2 Superparamagnetic iron oxide nanoparticles (SPIONs)	44
1.4.3 Iron doped ZnO NPs	46
1.4.4 CIS/ZnS quantum dots.....	47
1.5 SURFACE MODIFICATION OF QDs	48
1.6 POLYMERIC NANOPARTICLES.....	49
1.6.1 PLGA particles and their relationship to ZnO, SPIONS and CIS/ZnS.....	50
REFERENCES	51
CHAPTER II MATERIALS AND METHODS	60
II.1 Materials	60
II.2 SYNTHESIS	61
II.2.1 ZnO QDs synthesis	61
II.2.2 Fe-doped ZnO QDs synthesis.....	61
II.2.3 ZnO and FeZnO Surface modification with GPTMS	62
II.2.4 ZnO and FeZnO surface modification with Oleic Acid	63
II.2.5 Powder obtainment	63
II.2.6 Iron Oxide NPs	64
II.2.7 Synthesis of CIS/ZnS quantum dots.....	65

II.2.8 Synthesis and coupling of CIS/ZnS NPs with FeZnO NPs	67
II.2.9 Synthesis of PLGA-QDs particles	68
II.3 CHARACTERIZATION.....	70
II.3.1 Evaluation of luminescent Properties	70
II.3.2 Fourier Transform Infrared Spectroscopy (FTIR)	70
II.3.3 X-Ray Diffraction.....	70
II.3.4 Transmission Electron Microscopy (TEM)	70
II.3.5 Inductively Coupled Plasma Mass Spectrometry (ICP-MS)	71
II.3.6 Evaluation of particle size distribution and zeta potential.....	71
II.3.7 Magnetic Resonance Imaging	71
II.3.8 X-ray absorption spectroscopy (XAS).....	71
II.4 BIOLOGICAL ANALYZES	72
II.4.1 Cytotoxicity Assay using Resazurin Test.....	72
II.4.2 Uptake and fluorescence teste	72
REFERENCES	73
CHAPTER III. Study of PLGA particles containing NPs of ZnO and IO for bimodal image.....	75
III.1 INTRODUCTION	75
III.2 RESULTS AND DISCUSSION.....	75
III.2.1 Synthesis of ZnO NPs coated with Oleic Acid	75
III.2.2 Synthesis of IO NPs coated with Oleic Acid	80
III.2.3 PLGA:ZnO:IO particles	81
III.2.3.1 PLGA:IO	81
III.2.3.2 PLGA:ZnO.....	84
III.2.3.3 ZnO & IO interaction	88
III.2.3.4 PLGA:ZnO:IO size and luminescence study	89
III.2.4 Infrared analysis	94
III.2.5 TEM Analysis	94
III.2.6 MRI analysis	99
III.2.7 Zeta Potential analysis.....	102
III.3 Conclusion	103
REFERENCES	104
CHAPTER IV. Study of Nanoparticles of Fe-doped ZnO as bimodal agent for bioimaging.	107
IV.1 INTRODUCTION	107
IV.2 RESULTS AND DISCUSSION	108

IV.2.1 Iron precursor Analyse.....	108
IV.2.2 Fe-doped ZnO quantum dots synthesis	109
IV.2.2.1 Determination of the parameters of syntheses - iron concentration.....	109
IV.2.2.2 Determination of the Doping time by luminescence tests.....	113
IV.2.2.3 Luminescence tests with different iron source.....	116
IV.2.3 MRI study of FeZnO /GPTMS	119
IV.2.3.1 MRI study of FeZnO /GPTMS with different source of iron	119
IV.2.3.2 MRI study of FeZnO/GPTMS with different doping time	121
IV.2.3.3 MRI study of FeZnO adopting iron concentration between 0.1 to 1 %	127
IV.2.4 Characterization	129
IV.2.4.1 X-ray diffraction	129
IV.2.4.2 XAS analysis.....	131
IV.2.4 Fe-doped ZnO into PLGA particles	134
IV.2.4.1 FeZnO coated by OA	134
IV.2.4.2 PLGA:FeZnO Luminescence assays and size analyse.....	136
IV.2.4.3 TEM analyses.....	138
IV.2.4.4 MRI results.....	142
IV.3 Conclusion	144
REFERENCES	145
CHAPTER V. CIS/ZnS and Fe₃O₄ as bimodal contrast agent for biological imaging	148
V.1 INTRODUCTION	148
V.2 RESULTS AND DISCUSSION.....	148
V.2.1 CIS/ZnS synthesis	148
V.2.1.1 CIS/ZnS luminescent analyses	148
V.2.1.2 Infrared Analysis	150
V.2.1.3 Thermogravimetric analysis	151
V.2.2 PLGA:CIS/ZnS:IO particles.....	152
V.2.3.1 Interaction of CIS/ZnS and IO	152
V.2.3.3 TEM analysis.....	158
V.2.3.4 MRI analysis	159
V.2.2 Development of FeCIS / ZnS quantum dots.....	161
V.2.2.1 Infrared Analysis	161
V.2.2.2 Thermogravimetric analysis	162
V.2.2.3 Absorbance and Luminescence assay	164
V.2.3 FeZnO@CIS/ZnS Coupling	165
V.3 Conclusion.....	168

REFERENCES	168
CHAPTER VI – Preliminary evaluation of cytotoxicity and cellular uptake	172
VI 1 Introduction.....	172
VI.2 Results and Discussion.....	172
VI.2.1 Cytotoxicity assay for PLGA containing ZnO and IO NPs	172
VI.2.2 Uptake assay for PLGA containing ZnO and IO NPs.....	175
VI.2.3 Luminescence Stability of Fe-ZnO Quantum Dots Prior to Cellular Assays.....	181
VI.3 Conclusion	182
REFERENCES	183
CHAPTER VII – Final conclusions.....	185

INTRODUCTION

INTRODUCTION

Cancer represents a significant challenge to global public health. In 2022, approximately 20 million new cases of cancer were reported worldwide, with 9.7 million cancer-related deaths (BRAY BSC et al., 2024). Efforts in cancer prevention are essential for reducing the overall disease burden. Additionally, early detection holds critical importance in improving treatment efficacy and bolstering survival rates (SRINIVASA; SRINIVASA, 2023; VITORINO et al., 2023).

Diagnosing cancer in its early stages plays a fundamental role in effective treatment, allowing for a more favourable prognosis of the disease (PULUMATI et al., 2023). When cancer is identified early stages, treatment options are broader and less invasive, preventing it from spreading to other parts of the body, thereby increasing the chances of cure, and reducing the morbidity associated with treatment (PRIYADHARSHINI et al., 2023; TOBORE, 2020). Additionally, early cancer diagnosis enhances patients' quality of life. By being diagnosed and treated early, patients have access to appropriate medical and supportive interventions from the outset, which can help mitigate the side effects of treatment (WHITAKER, 2020).

Imaging techniques play an important role in cancer diagnosis, allowing for a detailed assessment of the body's internal structures. Among these techniques, we can mention radiography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasonography (BARENTSZ et al., 2016). X-rays are widely used due to their availability and speed, although they have limitations in detecting certain types of cancer and may involve exposure to ionizing radiation (FASS, 2008). On the other hand, CT provides detailed images and is effective in detecting tumors and metastases, but repeated use may pose risks due to radiation exposure (POWER et al., 2016). Meanwhile, ultrasound imaging, although safe and widely available, has limitations in visualizing deep structures (TENAJAS et al., 2023). On the other hand, MRI provides excellent soft tissue details with high resolution without using ionizing radiation, although they are more expensive and less accessible (ARNOLD et al., 2023). Additionally, MRI can be used to assess tumor response to treatment and monitor patient progress over time (LAU; CORRIE; GALLAGHER, 2022).

The fluorescence technique is another option that can be used as an imaging method for cancer diagnosis. Fluorescence is often employed in conjunction with contrast agents (CAs) that emit light when excited by a specific energy source. These CAs can be targeted to specific cancer cells or biological markers, allowing direct visualization of the tumor during surgical procedures or imaging exams (HELLEBUST; RICHARDS-KORTUM, 2012). Fluorescence offers high sensitivity and specificity, as well as real-time imaging, which can facilitate early detection of cancerous lesions and guidance during tumor removal surgery (MONDAL et al., 2014).

CAs are widely employed in medical imaging exams to enhance the visibility of anatomical structures and physiological processes. Among the most used are iodinated CAs and barium CAs, often utilized in CT to highlight vascular and abdominal structures, respectively (LUSIC; GRINSTAFF, 2013). They offer rapid availability and the ability to provide high-resolution images in a short amount of time. However, they carry the risk of allergic reactions, especially in patients sensitive to iodine, and the potential for adverse effects (AE) on the kidneys, particularly in patients with renal dysfunction (CHIU; CHU, 2022; “HEALTH EFFECTS - Toxicological Profile for Barium and Barium Compounds - NCBI Bookshelf”, [s.d.]; “Intravenous Radiocontrast Media: A Review of Allergic Reactions”, [s.d.]). Paramagnetic CAs, such as gadolinium-based CAs (GBCAs), are widely used in MRI to enhance images of organs and soft tissues, providing greater contrast in areas where they accumulate, however, the potential risk of gadolinium toxicity is a disadvantage in the use of this CA (IYAD et al., 2023).

The combination of two imaging diagnostic techniques using CAs offers significant advantages. Integrating different imaging modalities, such as fluorescence imaging and MRI, can provide complementary information about a particular pathology, allowing for a more comprehensive and accurate assessment (LI et al., 2019; MULDER et al., 2007). While fluorescence imaging is excellent for visualizing cellular and molecular structures based on light emission (ACUÑA-RODRIGUEZ; MENA-VEGA; ARGÜELLO-MIRANDA, 2022), MRI is a technique more effective, radiation-free, non-invasive imaging that provides three-dimensional (3D) visualization of tissues (FLORKOW et al., 2022). Additionally, the combination of imaging techniques can increase the sensitivity and specificity of diagnosis, enabling early

detection of lesions and abnormalities that may not be identified by a single imaging modality (MORATO et al., 2021).

Quantum dots (QDs) are semiconductor nanomaterials that exhibit unique optical properties, making them promising CAs in medical imaging (MATEA et al., 2017). Among the most used semiconductor QDs are cadmium sulfide (CdS) (GHASEMPOUR et al., 2023), cadmium selenide (CdSe) (HSU et al., 2023), and indium arsenide (InAs) (BAHMANI JALALI et al., 2022). These materials offer high quantum efficiency and light emission across a broad spectral range, making them ideal for biomedical imaging applications.

Although quantum dots (QDs) present promising properties in medical imaging, their application also poses significant challenges. For example, studies have shown that certain cadmium QDs may exhibit toxicity, raising concerns about their biological safety, and health risks due to potential cadmium ion release in biological environments (HU; ZHONG; HE, 2021). Furthermore, the persistence of these QDs in the body has also been documented, with studies demonstrating their accumulation in tissues over time, as observed in experiments with mice (LIU et al., 2011; LU et al., 2016; TANG et al., 2013). Another concern is the potential interaction of QDs with biological components such as proteins and enzymes, which may affect normal cellular function and compromise the validity of biological experiments. For example, cellular imaging studies have revealed that certain QDs can induce oxidative stress and DNA damage in human cells, emphasizing the need for careful assessment of their biocompatibility (FANG; TANG, 2024; ZHANG et al., 2015).

Zinc oxide (ZnO) and iron oxide (IO) emerge as highly promising compounds in the field of diagnostic imaging. With their distinct luminescent and magnetic properties (MP), respectively, these compounds offer significant potential to enhance medical imaging techniques. For example, ZnO can be used as a CA in fluorescence-based imaging, standing out for its high colloidal stability and strong luminescent emission (ZHANG; XIONG, 2015).

On the other hand, IO is widely employed in MRI due to its ability to alter tissue relaxation times, providing high-resolution and high-contrast images (RAHMAN, 2023). Iron oxide nanoparticles induce magnetic effects when an external magnetic field is applied. Due to their superparamagnetic properties, these nanoparticles predominantly

exhibit spin-spin (T2) magnetic relaxation. This results in enhanced T2 contrast in magnetic resonance imaging (MRI). The superparamagnetism of the iron oxide nanoparticles allows for better image resolution and contrast in T2-weighted MRI scans, making them highly effective as contrast agents.

Incorporating iron (Fe) and zinc (Zn)-based polymeric systems opens a vast field of possibilities in the development of CAs for diagnostic imaging. The combination of these elements in polymeric systems offers several advantages, such as enhanced colloidal stability, biocompatibility, and vectorization capability. For example, the use of polymers like poly(lactide-co-glycolide) (PLGA) as a matrix for nanoparticles (NPs) allows for the controlled delivery and increasing their efficacy and minimizing toxicity. Additionally, the presence of the polymer can improve the dispersion of NP in the biological medium, facilitating their interaction with target cells.

PLGA facilitates dispersion in biological media due to its biocompatibility and biodegradability, which enhance its interaction with biological tissues. Its hydrophilic and hydrophobic balance allows for better solubility and stability in aqueous environments. Moreover, PLGA nanoparticles can be engineered to have surface modifications that improve their dispersibility and reduce aggregation. This results in more uniform distribution and controlled release of encapsulated drugs or agents, making PLGA an ideal material for biomedical applications (DING; ZHU, 2018).

The CIS/ZnS compound, a combination of copper, indium, sulfur, and zinc sulfide, emerges as effective option for fluorescence imaging applications (CHOI et al., 2015; DENG et al., 2012; LV et al., 2016). Its optical properties, such as high luminescence and colloidal stability, can be notice it as a promising alternative to traditional CAs. When excited by an appropriate energy source, CIS/ZnS emits visible light and near-red wavelength, offering a valuable tool for studies in cell biology and medical diagnosis (LV et al., 2016).

The objective of this study was to synthesize iron and zinc based NPs exhibiting robust visible emission and enhanced MPs, while ensuring stability in biological environments. This was achieved through surface modification techniques or integration into polymeric nanosystems, aimed at enhancing their suitability for bioimaging applications. This thesis has been divided into 4 important chapters.

The first part (Chapter III) discussed the incorporation of ZnO and IO nanosystem coated with oleic acid for incorporation into a polymeric system. The NPs were coated with oleic acid for possible dispersion in an organic solvent, and it was possible to proceed with the synthesis of polymers containing both particles using a simple emulsion and solvent evaporation method. At this stage, the appropriate proportions for suitable luminescence and MRI between the QDs were studied. Infrared, absorbance, fluorescence (excitation and emission), MRI, and transmission electron microscopy (TEM) techniques were used to characterize the samples.

In Chapter IV, the combination of both elements in the same compound was investigated. A doping method was used in which ZnO NPs were doped with iron ions and the luminescent and MPs of this material were verified. Previously, the ZnO materials studied were evaluated by modifying them with a silane-based compound, GPTMS, which ensured suitable dispersion in water. The same material was used to modify the surface of the iron-doped zinc oxide NPs (FeZnO NPs). These NPs were also modified with oleic acid for incorporation into polymeric particles.

It is known that ZnO produced with a size of 4 nm has a suitable luminescence at a wavelength of 540 nm and that the excitation range of this compound is up to 350 nm, which can pose some risks for diagnostic imaging. Therefore, in Chapter V, another component based on CIS/ZnS was studied, which has a suitable emission in the orange region, around 630 nm, and an excitation wavelength in the region of 525 nm. This compound and the IO were incorporated into polymer particles for possible use in bimodal imaging.

The Chapter VI closes with preliminary studies of cytotoxicity assays and cellular uptake using THP-1 cells, phagocytes with efficient uptake capacity, which were investigated with molecules discussed in previous chapters.

REFERENCES

ACUÑA-RODRIGUEZ, J. P.; MENA-VEGA, J. P.; ARGÜELLO-MIRANDA, O. Live-cell fluorescence spectral imaging as a data science challenge. **Biophysical Reviews**, v. 14, n. 2, p. 579, 2022.

ARNOLD, T. C. et al. Low-field MRI: Clinical promise and challenges. **Journal of Magnetic Resonance Imaging**, v. 57, n. 1, p. 25, 2023.

BAHMANI JALALI, H. et al. Indium arsenide quantum dots: an alternative to lead-based infrared emitting nanomaterials. **Chemical Society Reviews**, v. 51, n. 24, p. 9861–9881, 2022.

BARENTSZ, J. et al. Commonly Used Imaging Techniques for Diagnosis and Staging, v. 24, n. 20, p. 3234–3244, 2016.

BRAY BSC, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2024.

CHIU, T. M.; CHU, S. Y. Hypersensitivity Reactions to Iodinated Contrast Media. **Biomedicines**, v. 10, n. 5, 2022.

CHOI, H. S. et al. Highly luminescent, off-stoichiometric $\text{Cu}_x\text{In}_y\text{S}_2/\text{ZnS}$ quantum dots for near-infrared fluorescence bio-imaging. **RSC Advances**, v. 5, n. 54, p. 43449–43455, 2015.

DING, D.; ZHU, Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. **Materials Science and Engineering: C**, v. 92, p. 1041–1060, 2018.

DENG, D. et al. High-quality $\text{CuInS}_2/\text{ZnS}$ quantum dots for in vitro and in vivo bioimaging. **Chemistry of Materials**, v. 24, n. 15, p. 3029–3037, 2012.

FANG, Q.; TANG, M. Oxidative stress-induced neurotoxicity of quantum dots and influencing factors, 2024.

FASS, L. Imaging and cancer: A review. **Molecular Oncology**, v. 2, n. 2, p. 115, 2008.

FLORKOW, M. C. et al. Magnetic Resonance Imaging Versus Computed Tomography for Three-Dimensional Bone Imaging of Musculoskeletal Pathologies: A Review. **Journal of Magnetic Resonance Imaging**, v. 56, n. 1, p. 11, 2022.

GHASEMPOUR, A. et al. Cadmium Sulfide Nanoparticles: Preparation, Characterization, and Biomedical Applications. **Molecules**, v. 28, n. 9, 2023.

HEALTH EFFECTS - Toxicological Profile for Barium and Barium Compounds - NCBI Bookshelf. Available in: <<https://www.ncbi.nlm.nih.gov/books/NBK598777/>>. Access in: 15 abr. 2024.

HELLEBUST, A.; RICHARDS-KORTUM, R. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics. v. 7, n. 3, p. 429–445, 2012.

HSU, J. C. et al. Nanomaterial-based contrast agents. **Nature Reviews Methods Primers** 2023 3:1, v. 3, n. 1, p. 1–21, 2023.

HU, L.; ZHONG, H.; HE, Z. Toxicity evaluation of cadmium-containing quantum dots: A review of optimizing physicochemical properties to diminish toxicity. **Colloids and Surfaces B: Biointerfaces**, v. 200, p. 111609, 2021.

Intravenous Radiocontrast Media: A Review of Allergic Reactions. Available in: <<https://www.uspharmacist.com/article/intravenous-radiocontrast-media-a-review-of-allergic-reactions>>. Access in: 15 abr. 2024.

IYAD, N. et al. Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review. **European Journal of Radiology Open**, v. 11, p. 100503, 2023.

LAU, D.; CORRIE, P. G.; GALLAGHER, F. A. MRI techniques for immunotherapy monitoring. **Journal for ImmunoTherapy of Cancer**, v. 10, n. 9, p. e004708, 2022.

LI, H. et al. Bimodal Fluorescence-Magnetic Resonance Contrast Agent for Apoptosis Imaging. **Journal of the American Chemical Society**, v. 141, n. 15, p. 6224–6233, 2019.

LIU, W. et al. CdSe Quantum Dot (QD)-Induced Morphological and Functional Impairments to Liver in Mice. **PLOS ONE**, v. 6, n. 9, p. e24406, 2011.

LU, Y. et al. CdSe/ZnS quantum dots induce hepatocyte pyroptosis and liver inflammation via NLRP3 inflammasome activation. **Biomaterials**, v. 90, p. 27–39, 2016.

LUSIC, H.; GRINSTAFF, M. W. X-Ray Computed Tomography Contrast Agents. **Chemical reviews**, v. 113, n. 3, p. 1641–1666, 2013.

- LV, G. et al. Near-Infrared Emission CuInS/ZnS Quantum Dots: All-in-One Theranostic Nanomedicines with Intrinsic Fluorescence/Photoacoustic Imaging for Tumor Phototherapy. **ACS Nano**, v. 10, n. 10, p. 9637–9645, 2016.
- MATEA, C. T. et al. Quantum dots in imaging, drug delivery and sensor applications. **International Journal of Nanomedicine**, v. 12, p. 5421, 2017.
- MONDAL, S. B. et al. Real-Time Fluorescence Image-Guided Oncologic Surgery. **Advances in Cancer Research**, v. 124, p. 171–211, 2014.
- MORATO, Y. L. et al. Recent Advances in Multimodal Molecular Imaging of Cancer Mediated by Hybrid Magnetic Nanoparticles. **Polymers**, v. 13, n. 17, 2021.
- MULDER, W. J. M. et al. Magnetic and fluorescent nanoparticles for multimodality imaging, v. 2, n. 3, p. 307–324, 2007.
- POWER, S. P. et al. Computed tomography and patient risk: Facts, perceptions and uncertainties. **World Journal of Radiology**, v. 8, n. 12, p. 902, 2016.
- PRIYADHARSHINI, N. et al. A novel hybrid Extreme Learning Machine and Teaching–Learning-Based Optimization algorithm for skin cancer detection. **Healthcare Analytics**, v. 3, p. 100161, 2023.
- PULUMATI, A. et al. Technological advancements in cancer diagnostics: Improvements and limitations. **Cancer Reports**, v. 6, n. 2, 2023.
- RAHMAN, M. Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine. **Nanotheranostics**, v. 7, n. 4, p. 424, 2023.
- SRINIVASA, J.; SRINIVASA, F. K. Emerging Strategies in Cancer Prevention: Focus on Targeted Interventions and Lifestyle Modifications. **Journal of Oncology Research**, v. 5, n. 2, 2023.
- TANG, Y. et al. The role of surface chemistry in determining in vivo biodistribution and toxicity of CdSe/ZnS core–shell quantum dots. **Biomaterials**, v. 34, n. 34, p. 8741–8755, 2013.
- TENAJAS, R. et al. Recent Advances in Artificial Intelligence-Assisted Ultrasound Scanning. **Applied Sciences** 2023, v. 13, n. 6, p. 3693, 2023.

TOBORE, T. O. On the need for the development of a cancer early detection, diagnostic, prognosis, and treatment response system. **Future Science OA**, v. 6, n. 2, 2020.

VITORINO, R. et al. Diagnostic and monitoring applications using near infrared (NIR) spectroscopy in cancer and other diseases. **Photodiagnosis and Photodynamic Therapy**, v. 42, p. 103633, 2023.

WHITAKER, K. Earlier diagnosis: the importance of cancer symptoms. **The Lancet Oncology**, v. 21, n. 1, p. 6–8, 2020.

ZHANG, T. et al. Threshold Dose of Three Types of Quantum Dots (QDs) Induces Oxidative Stress Triggers DNA Damage and Apoptosis in Mouse Fibroblast L929 Cells. **International Journal of Environmental Research and Public Health** 2015, v. 12, n. 10, p. 13435–13454, 2015.

ZHANG, Z. Y.; XIONG, H. M. Photoluminescent ZnO Nanoparticles and Their Biological Applications. **Materials**, v. 8, n. 6, p. 3101, 2015.

CHAPTER VII

Final conclusions

CHAPTER VII – Final conclusions

The aim of this work was the development of iron- and zinc-based nanosystems as agents for diagnostic imaging, due to the suitable luminescence properties of the Zn-based compounds and the suitable Mp of the iron-based compounds. The nanometric particles have special properties at the level of the atom. In addition to the use of components with low toxicity in comparison to the QDs that are currently used, such as Cd and Gd.

A system based on ZnO and IO was developed as a first step. For this purpose, a particle system based on polylactide coglycolide acid (PLGA) copolymer was chosen. This copolymer is biocompatible, widely used as a drug carrier, and shows suitable selectivity for cancer cells. A study to modify the NP surface with oleic acid was performed.

The NPs were suitably modified with oleic acid. PLGA particles were prepared. The PLGA particles were prepared using a simple emulsion and solvent evaporation method that involves easily accessible, inexpensive components and simple synthesis without using temperature. The particles showed a circular shape with adequate size from the TEM and DLS results, which can be used as drug carriers.

From the results, it has been observed that there is an interaction between the IO NPs and the ZnO NPs. The luminescence properties of ZnO are lost with the increased presence of iron. However, a study of the ratio of ZnO to IO was performed and it was found that the nominal ratio of PLGA:ZnO:IO 10:6:1 (w:w:w, mg) is important to get luminescence intensity in the PLGA particles. The luminescence intensity of the ZnO is affected below this nominal ratio in relation to ZnO. However, at this amount, ZnO luminescence is preserved and with the results presented in MRI measurements, this ratio was sufficient to show a suitable T2 effect.

The polymeric system was tested on TPH1 cells for uptake and cytotoxicity. The uptake was efficient as after 4 hours incubation, the cells were luminescent and the loading did not induce toxicity.

The doping of ZnO with iron was studied as the production of PLGA particles loaded with IO and ZnO might not be satisfactory as with time, both imaging tags can be released and then label different cells or cells compartment. An attempt was made to

observe how the iron interact with the ZnO through a doping process. The sol-gel process and ultrasound were used for the doping process. The molar concentration of the iron was observed in relation to the molar concentration of the zinc. It was observed that as the concentration of the doped iron increases, the ZnO loses its luminescence. A minimum amount of iron was observed to be sufficient for ZnO to keep its luminescence. In addition, it has been observed that the doping time can influence the properties of this material. It has been observed that the time of addition of the dopant to the medium after the start of the reaction can influence the luminescence properties of this material. To maintain the luminescent properties of the material, it is believed that the formation of the ZnO core is essential. The luminescence intensity is increased with the addition of 0.1% iron ions in the solution. It has been shown that the particle size of the ZnO does not change when the iron content is between 0 and 1 %.

In addition, the Mp of the material were also observed by means of MRI. The FeZnO NPs with GPTMS surface modification were able to produce T2 and T1 effects. These effects are not observed with pristine ZnO NPs. The effect increases with increasing iron concentration. However, 0.1% is sufficient to produce these effects.

About CIS/ZnS NPs. Attempts have been made to dope the CIS/ZnS composite with iron. However, it has been observed that the material properties are lost with the Fe:In:Cu ratio used. In addition, the crystalline structure is modified. Different mass losses were observed in the thermogravimetry spectra. In the processing of CIS/ZnS and IO NPs. These particles have been incorporated into the polymer system of PLGA. The luminescence properties of CIS/ZnS in the presence of IO were not affected. The luminescence maximum was observed at 650 nm. The Mp showed suitable T2 contrast due to the presence of IO.

The results of this study demonstrate the successful development of iron- and zinc-based nanosystems, which combine luminescent and magnetic properties for diagnostic imaging applications. The cost-effective synthesis ensured the formation of biocompatible nanometric particles that are efficient in cellular uptake without toxicity. The optimization of ZnO and IO ratios in PLGA particles resulted in preserved luminescence and suitable T2 effect, highlighting the potential of these systems as multimodal imaging agents. The modification with oleic acid and the iron doping study further reinforces the versatility and efficacy of these materials, offering a promising and less toxic alternative to conventional imaging agents.